Creator: Help Dementia Editorial Team
Published: 2026-04-12T04:46:15

Reviewed by the Help Dementia Editorial Team — our editors review every article for accuracy against guidance from the National Institute on Aging, the Alzheimer’s Association, and peer-reviewed sources.

Biomarker-driven trial sits at the center of this dementia and brain health question.

Biomarker-driven trial enrollment significantly improves the efficiency of Alzheimer’s disease research by allowing researchers to identify and recruit the right patients at the right disease stage. Rather than enrolling participants based primarily on cognitive symptoms alone, researchers now use objective biological markers—measurable indicators of disease activity in the brain—to screen candidates and track treatment response. This shift has transformed clinical trial design: 84% of active disease-targeted therapeutic Alzheimer’s trials now incorporate fluid, imaging, and digital biomarkers for both eligibility and outcome measurement, making enrollment faster and study results more reliable. The practical impact is substantial.

A 2025 study using AI-guided patient stratification in the AMARANTH trial demonstrated that recruiting patients at earlier stages of neurodegeneration—identified through biomarkers—achieved a 46% slowing of cognitive decline compared to traditional approaches. This means researchers can now select participants whose disease stage matches the treatment being tested, reducing the number of patients needed to show benefit and accelerating the path to regulatory approval. Biomarker-driven enrollment represents a fundamental shift from the old model of trial recruitment. Where researchers once waited for patients to develop moderate cognitive impairment, they can now detect disease activity years earlier, before substantial brain damage occurs. This allows drug developers to test interventions at stages where they are most likely to succeed—addressing a major source of Alzheimer’s trial failure.

How Are Biomarkers Used to Screen Alzheimer’s Trial Participants?
Blood-Based Biomarkers and the Efficiency Advantage
The A/T/N Framework and Precision Patient Selection
Balancing Speed and Inclusivity in Recruitment
The Hidden Challenges in Biomarker-Driven Enrollment
Real-World Trial Examples and Implementation
The Future of Biomarker-Driven Research and Personalized Trials
Conclusion

How Are Biomarkers Used to Screen Alzheimer’s Trial Participants?

Biomarkers serve two critical functions in modern Alzheimer’s trials: identifying eligible participants and measuring whether treatment works. In inclusion criteria, 58% of disease-targeted Alzheimer’s trials now require evidence of Alzheimer’s pathology before enrollment. The most commonly used pathway is A/T/N biomarkers—amyloid (A), tau (T), and neurodegeneration (N)—which are measured in blood, cerebrospinal fluid, or brain imaging. About 51% of disease-targeted trials incorporate these A/T/N biomarkers as part of their eligibility criteria, meaning a patient may be excluded from a trial simply because their biomarker profile doesn’t match the study design, even if they have cognitive symptoms. Blood-based biomarkers have become the primary screening tool because they are far more practical than older alternatives.

Plasma phosphorylated tau and amyloid assays achieve over 90% accuracy in identifying Alzheimer’s pathology, comparable to expensive PET imaging or invasive spinal taps, yet they can be performed at any clinic. This scalability has opened enrollment to participants who live far from research centers equipped with imaging scanners. A patient in a rural area can now have blood drawn at their local hospital, with results returned to a research coordinator within days. The challenge, however, is that biomarker requirements have made eligibility criteria more complex. While precision in patient selection improves trial efficiency, it has not solved the recruitment bottleneck. Many patients who meet cognitive criteria for a trial still fail to meet biomarker thresholds, requiring larger screening pools and longer enrollment periods.

How Are Biomarkers Used to Screen Alzheimer's Trial Participants?

Blood-Based Biomarkers and the Efficiency Advantage

Blood tests for Alzheimer’s biomarkers represent a turning point in trial recruitment because they eliminate the need for costly imaging or spinal procedures just to determine if someone qualifies. Plasma phosphorylated tau-181 and phosphorylated tau-217, along with amyloid-beta ratio measurements, can now be ordered in an outpatient setting, making initial screening far less burdensome for participants. The >90% accuracy of these assays means researchers can confidently exclude patients without Alzheimer’s pathology before subjecting them to more invasive biomarker confirmation or baseline cognitive testing. However, blood-based biomarkers have introduced a new logistical reality: not all hospitals and clinics have access to these specialized assays.

Many regions still lack local testing capacity, forcing some participants to travel to research sites for biomarker screening—ironically reintroducing the travel burden that blood tests were supposed to solve. Additionally, standardization of these assays across different laboratories remains incomplete, meaning results from one testing site may not be directly comparable to another, occasionally requiring repeat testing before enrollment. The economic efficiency gain is significant nonetheless. 36% of disease-targeted Alzheimer’s trials now use biomarkers as primary outcome measures, meaning the primary evidence of treatment benefit is a change in biomarker level rather than cognitive testing scores. This allows researchers to complete trials faster because biomarker changes often appear before cognitive improvement becomes measurable—in some cases, reducing trial duration from 18 months to 12 months or less.

The A/T/N Framework and Precision Patient Selection

The A/T/N framework—amyloid, tau, and neurodegeneration—has become the standard language for categorizing Alzheimer’s pathology across the entire disease spectrum, from preclinical stages through dementia. This classification allows researchers to recruit patients with specific pathology patterns. A trial targeting early tau accumulation might enroll only participants with elevated phosphorylated tau but relatively preserved amyloid levels, ensuring that everyone in the study has the specific pathology the drug is designed to treat. This precision means smaller trials can show meaningful effects because the comparison group is genuinely comparable. The AMARANTH trial exemplifies how A/T/N stratification enables better outcomes.

By using AI to identify patients in early stages of neurodegeneration (the “N” component of A/T/N), researchers were able to demonstrate a 46% slowing of cognitive decline—a result that likely would not have emerged if the trial had enrolled a mixed population with varying disease stages. Early-stage patients still have cognitive reserve and faster progression rates, making treatment effects more measurable. A limitation of A/T/N stratification is that it defines disease biology but not clinical phenotype. Two patients may have identical biomarker profiles but completely different symptoms—one primarily forgetting names, the other struggling with spatial navigation. Biomarker-driven enrollment optimizes for biological homogeneity, not symptomatic similarity, which can sometimes create enrolled populations that feel clinically diverse even though they are biologically uniform.

The A/T/N Framework and Precision Patient Selection

Balancing Speed and Inclusivity in Recruitment

Biomarker-driven enrollment streamlines the research process but creates a tradeoff with diversity. When trials require specific biomarker profiles, they inevitably exclude people whose cognitive symptoms don’t align with the underlying pathology—for instance, someone with significant memory loss but amyloid-negative scans. While this improves statistical power for disease-modifying treatments, it means some people with Alzheimer’s-like symptoms never qualify for trials testing novel therapies. Researchers must decide whether to optimize for detecting treatment effect (narrow biomarker criteria) or for ensuring that a trial represents the full spectrum of dementia presentation (broader criteria). Sites that excel in biomarker-driven recruitment often implement a two-stage screening process. The first stage uses blood biomarkers as a rapid filter, eliminating candidates unlikely to qualify before they invest time in cognitive testing.

The second stage confirms eligibility with additional imaging or cognitive assessment only for those who pass biomarker screening. This approach cuts screening time dramatically compared to traditional cognitive testing first. But it requires up-front investment in blood-testing infrastructure—an expense not all sites can afford, widening the gap between well-resourced research centers and smaller clinics. The data suggests this model is working: 84% of active disease-targeted trials now use biomarkers at some stage. Yet recruitment remains the biggest bottleneck for most trials, indicating that biomarker efficiency has not fully solved the problem. Sites still struggle with study partner requirements (many trials require a caregiver present), repeated visits, and the time commitment involved—issues that biomarkers alone cannot address.

The Hidden Challenges in Biomarker-Driven Enrollment

One underappreciated challenge is biomarker variability across research sites. While blood-based assays are standardized, they are not yet universally identical. A participant’s plasma phosphorylated tau result from one laboratory might differ from another’s, and interpretation varies slightly depending on the assay platform used. This variation occasionally forces researchers to repeat biomarker testing or use conservative thresholds, adding cost and delay. Harmonization efforts are ongoing, but most 2025 trials still work with slight methodological differences across sites. Another operational reality that biomarkers do not solve is the ongoing burden of trial participation. Even after biomarker-confirmed enrollment, participants face frequent visits, cognitive testing, and sometimes imaging follow-ups.

The requirement for a study partner—typically a spouse or adult child—remains mandatory for most Alzheimer’s trials, excluding solo-living older adults or those without reliable caregivers. Biomarker efficiency has made the screening phase faster, but the active trial phase remains logistically demanding. A patient who qualifies based on a blood test may still drop out due to travel, time, or caregiver unavailability. A final consideration is overdiagnosis risk. As biomarker screening becomes more sensitive and accessible, there is potential for identifying people with Alzheimer’s pathology who may never develop symptoms. Some trials now enroll cognitively normal individuals with preclinical biomarker evidence of amyloid and tau. While scientifically valuable, this raises ethical questions about labeling asymptomatic people with a “disease” and enrolling them in drug studies when benefit is uncertain.

The Hidden Challenges in Biomarker-Driven Enrollment

Real-World Trial Examples and Implementation

The AMARANTH trial provides a concrete model of biomarker-driven efficiency in action. Rather than enrolling a heterogeneous group of symptomatic patients, AMARANTH used biomarker-defined inclusion criteria and AI stratification to identify patients at a specific disease stage. The result was a 46% slowing of cognitive decline—a magnitude of effect substantially larger than many earlier trials that enrolled broader populations.

This suggests that precision enrollment through biomarkers can meaningfully improve treatment signal detection. Similarly, many recent tau-targeted trials (lecanemab, remternetug) have built biomarker confirmation directly into their screening protocols, requiring evidence of elevated amyloid and tau at baseline. This contrasts sharply with older donepezil trials that enrolled based primarily on cognitive diagnosis alone. The newer approach has reduced the time to enrollment and improved participant retention because patients know they have the specific pathology the drug addresses.

The Future of Biomarker-Driven Research and Personalized Trials

Biomarker-driven enrollment is likely to deepen as assays become more specific and accessible. Future trials may move toward even narrower cohorts defined by combinations of biomarkers—not just A/T/N status but also specific tau phosphorylation sites, inflammatory markers, or genetic risk profiles.

This precision will further improve statistical power for narrow indications but may also further fragment the trial landscape, making recruitment even more challenging for some populations. The broader trend suggests a shift from “one drug for Alzheimer’s” to “multiple drugs for specific biological subtypes.” This personalization mirrors advances in cancer treatment, where biomarker-driven selection has become standard. For dementia research, this means more efficient trials, faster approvals for narrowly indicated treatments, and ultimately better-matched therapies for individual patients—but only if enrollment challenges are solved and biomarker infrastructure extends to all communities, not just research-rich centers.

Conclusion

Biomarker-driven trial enrollment has fundamentally changed how Alzheimer’s disease research identifies and enrolls participants, making the process faster, more objective, and scientifically more rigorous. Blood-based biomarkers now allow researchers to screen for disease pathology at any clinic, and stratification by A/T/N biomarkers ensures that enrolled participants share the biological characteristics the treatment is designed to address. The results speak for themselves: 84% of active disease-targeted trials now use biomarkers, and approaches like AI-guided stratification have achieved substantial improvements in treatment efficacy—a 46% slowing of cognitive decline in early-stage patients.

Yet biomarker efficiency has not solved the fundamental recruitment challenge in Alzheimer’s research. Study partner requirements, cognitive testing burdens, and frequent site visits remain obstacles that even the most advanced biomarker screening cannot overcome. For participants and researchers alike, the next frontier is streamlining the full trial experience—not just screening, but also follow-up assessments and engagement strategies—to ensure that precision enrollment translates into sustainable, diverse participant populations across all communities.